Novartis AG (NVS) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$150.72

From 52W high−10.91%

Volume1.78M

Market cap$285.54B

P/E (TTM)22.6x

P/S (TTM)5.1x

Div yield2.05%

Key dataOct 19, 2026

Open

$150.72

From 52W high

−10.91%

Volume

1.78M

Market cap

$285.54B

ValuationView details →

P/E (Fwd)

15.5x

EV/EBITDA

14.7x

P/E (TTM)

22.6x

RSI (14)

61.6

MomentumView details →

1D Return

−0.26%

YTD Return

+9.04%

SummaryUpdated Jun 1, 2026

Novartis AG (NYSE:NVS) is a Swiss multinational pharmaceutical corporation founded in 1996 through the merger of Ciba-Geigy and Sandoz. Headquartered in Basel, Switzerland, Novartis has evolved into one of the world's largest pharmaceutical companies, focusing on innovative prescription medicines across multiple therapeutic areas. The company completed a significant strategic transformation in 2023 by spinning off its generics division Sandoz, allowing it to focus entirely on developing and commercializing breakthrough treatments for serious diseases.

Ask drillr about Novartis AG →

ValuationView details →

P/E (Fwd)

15.5x

P/E (TTM)

22.6x

EV/EBITDA

14.7x

EV/Sales

5.9x

P/S (TTM)

5.1x

P/B (TTM)

6.9x

ProfitabilityView details →

Gross Margin

74.44%

Net Margin

22.93%

EBITDA Margin

40.01%

ROE (TTM)

30.71%

ROA (TTM)

10.46%

Asset Turnover

0.46x

GrowthView details →

Revenue YoY

+0.81%

EPS YoY

−3.48%

FCF YoY

−5.87%

Revenue CAGR 3Y

+8.04%

EPS CAGR 3Y

+31.48%

EBITDA YoY

−1.98%

MomentumView details →

1D Return

−0.26%

YTD Return

+9.04%

1Y Return

+14.07%

RSI (14)

61.6

vs 50D SMA

+1.49%

vs 200D SMA

−0.55%

Capital & dividendView details →

Debt/Equity

1.18x

Current Ratio

0.86x

Quick Ratio

0.67x

Div Yield

2.05%

Div Rate

$3.08

Div Growth 1Y

−5.98%

EarningsView details →

EPS (Actual)

$2.41

EPS Surprise

11.06%

Beats (12Q)

9/12

Next Q EPS Est

$2.21

Avg Surprise (4Q)

2.27%

Rev Surprise

2.43%

Financials snapshotView financials →

Revenue (TTM)

55.63B

Net Income (TTM)

12.76B

Op. CF (TTM)

18.39B

Next earningsOct 27, 2026 →

Latest newsMore news →

NOVARTIS AG ended a mid-stage trial of Fabhalta targeting a serious kidney condition.3d ago

The UK High Court rejected ACCORD HEALTHCARE LIMITED’s challenge to NOVARTIS AG’s supplementary protection certificate for the combination of sacubitril and valsartan.6d ago

Similar companies

AstraZeneca PLCAZN Merck & Co., Inc.MRK Amgen Inc.AMGN Gilead Sciences, Inc.GILD Novo Nordisk A/SNVO Pfizer Inc.PFE Find similar companies →

Latest newsMore news →

NOVARTIS AG ended a mid-stage trial of Fabhalta targeting a serious kidney condition.3d ago The UK High Court rejected ACCORD HEALTHCARE LIMITED’s challenge to NOVARTIS AG’s supplementary protection certificate for the combination of sacubitril and valsartan.6d ago